New scan could spot myeloma lesions better than current tests

NCT ID NCT07353554

Not yet recruiting Diagnosis Sponsor: Peking Union Medical College Hospital Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a new type of PET/CT scan that uses a special tracer (68Ga-BCMA nanobody) to find multiple myeloma lesions in the body. Researchers will compare it to the standard FDG-PET/CT scan in 30 patients with newly diagnosed or relapsed multiple myeloma. The goal is to see if the new method detects more lesions and helps predict how the disease will progress.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: 68Ga-NOTA-BCMA nanobody (a radioactive tracer for PET/CT imaging)
What this could lead to: If successful, this could provide a more sensitive and specific imaging test for multiple myeloma, helping doctors detect disease earlier and choose better treatments.
What could go wrong: This is a small, early-phase study with only 30 participants, so results may not apply to all patients. The new tracer may not detect all lesions or may have unexpected side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA (MM) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE MYELOMA (MM)

Contacts and locations

Locations

Peking Union Medical College

Beijing, 100730, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.